Med Tech Antibody Id

Biotech Stocks Reporting on Breast Cancer Treatments; (OTC: AEMD), (NASDAQ ...

Point Roberts, WA-September 23, 2011 - Investorideas.com, a search portal for investors who specialize in biotechnology research and industry, including pharmaceutical stocks, issues an update of recent news and Biotech Pharmaceuticals and medical technology stocks reporting on developments in the treatment of breast cancer.Aethlon Medical (OTCBB: AEMD), a pioneer in developing therapeutic filtration devices, announced this week HER2osome ™, a new medical device strategy to inhibit the growth of HER2 + breast cancer, which is characterized by an aggressive growth and poor prognosis resulting from the increase in expression of the HER2 protein. Breast cancer is the most common form of invasive cancer in women. HER2 + breast cancer is about 25% of the diagnosis of breast cancer news.The goal of therapy is HER2osome ™ reduces the simultaneous presence of circulating exosomes and HER2 breast cancer, who have increasingly recognized as playing pivotal role in the development and progression of breast cancer. The researchers report that breast cancer exosomes suppress the immune response, stimulate angiogenesis, contributes to the spread of metastasis, and inhibiting the therapeutic benefit of Herceptin (trastuzumab) treatment with monoclonal antibodies against HER2 main + breast cancer.As a candidate therapeutic complement, ™ HER2osome supply to meet an unmet medical need and improve the benefit of treatment with Herceptin and chemotherapy the level of care without adding a drug toxicity or interactions risks.Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) announced Monday announced top-line data of the first part of a two-part of the Phase 1 SPI-1620 in combination with docetaxel was presented during an oral presentation at the 12th International Conference on Endothelin, held in Cambridge, UK, from September 11-14, 2011. The first part of the study was completed while the second part is in progress.The main objective of this Phase 1 study was to evaluate the safety and tolerability of SPI-1620 administered to patients with recurrent or progressive carcinoma who failed all standard therapies. The secondary objectives of the study include the evaluation of pharmacokinetic and pharmacodynamic profiles of SPI-1620 and identify the optimal dose of SPI-1620 for use in future Phase 2 studies. A total of 30 patients were enrolled in this study.Patients were aged from 41 to 77 years (median 61), and had prostate cancer (9 / 30), breast cancer (3 / 30), women reproductive malignancies (4 / 30), gastrointestinal cancer tract (3 / 30), and pancreatic cancer (2 / 30), among others, the Company types.Roxy Pharmaceuticals (Nasdaq: RXII) reported in a press release on Wednesday announced today that under licensed worldwide rights to develop and commercialize a protein-folate E39 (FBP) targeted vaccination to prevent recurrence in gynecological cancers, like ovarian and endometrial adenocarcinoma. He also said it continues to develop a vaccine against cancer for breast cancer.NeuVax is derived from the HER2 E75 peptide combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF). Treatment with NeuVax stimulates cytotoxic (CD8 +) T cells in a very specific target cells expressing any level of the protein HER2. NeuVax is given as an intradermal injection once a month for six months, followed by a booster every six months.Based on a Phase 2 successfully, which reached its primary endpoint of disease-free survival (DFS), the FDA granted NeuVax a Special Protocol Assessment (SPA) for its phase 3 CURRENT (prevention of recurrence in the early stages, the node-positive breast cancer study with low to intermediate expression of HER2 with NeuVax (TM) treatment). The Phase 3 trial is expected to begin in the first half of biotechnology 2012.Generex Corporation (OTCBB: GNBT) (www.generex.com) wholly owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), announced today that its lead drug candidate AE37, a new vaccine HER-2/neu-targeted currently in Phase II development for the treatment of breast cancer, is featured in the October 2011 Issue of Scientific American in an article entitled "a new ally against cancer" by Eric von Hofe, Ph.D., President of Antigen Express.Biotech Snapshot investors for Aethlon Medical (OTCBB: AEMD) The Aethlon Medical Mission is to create innovative medical devices that meet unmet medical needs in cancer, infectious diseases, and other deadly diseases.Aethlon ADAPT ™ platform provides the technological basis for a new class of drugs that target the selective elimination of the disease allowing particles of the entire circulatory system. The Aethlon ADAPT ™ product portfolio includes the Hemopurifier ®, a first-class medical device broad-spectrum capacity against the exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and hepatitis C . For more information, please visit www.aethlonmedical.com. Visit the Investorideas.com showcase AEMD on http://www.investorideas.com / CO / AEMD Receive the latest biotechnology and alerts stock http://www.investorideas.com/Resources/Newsletter.asp stocks Biotechnology Research at the directory Biotech Stocks: http://www.investorideas.com / BIS / Stock_List. asp About InvestorIdeas.com: InvestorIdeas.com is a leading equity research by sector investors. Areas we cover include: energy reserves of clean, renewable technologies, biotechnology stocks, stocks of mines and gold, stocks of energy, water, technology, defense stocks, nanotechnology, Agriculture and gaming.Follow Investorideas.com on Twitter http://twitter.com/ #! / Investorideas Follow Investorideas.com http://www.facebook on Facebook.com / Investorideas Disclaimer / Disclosure: The Investorideas.com is a third party, news and research Our sites do not make recommendations, but offer information portals to research news, articles, lists of actions and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Aethlon Medical Inc. (OTC BB: AEMD) Biotech Showcase, biodefense and defense actions on Investorideas.com (one thousand five hundred dollars per month, five thousand dollars per month in 144 shares) effective March 15, 2011 BC residents and investors Responsibility: Effective September 15, 2008 - all investors in British Columbia should look at all the OTC and pink sheet listed companies for the accession of information materials and deposit new relevant documents on SEDAR. Read for more info: 800-665-0411 http://www.bcsc.bc.ca/release.aspx?id=6894 - Source - www.Investorideas.

timing the stem cell opportunity (medtech insight)

01/09/2007

Medtech Insight - Companies are parallels between the industry of monoclonal antibodies and stem cells, and they try to find a balance between earning an interest in a field with enormous potential, but not too soon. Stem cells have the potential to treat some of the major degenerative diseases of the cardiovascular, neurological, orthopedic segments - markets worth billions in double digits, according to a recent report on tissue engineering, issued by Medtech Insight. No company wants to be left behind.

For $ 85, purchase this 1479-word Article as a PDF, and receive immediate delivery via email. See an article in the full sample.

Smile i-D, fashion and style : the best from 20 years of i-D

Antibody engineering, methods and protocols

Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer

Ramadan and Id-ul-Fitr

Id, The True You